Nav: Home

Countdown economist and parasitologist call for efficient and equitable control of NTDs

June 10, 2016

The continuing permanence of major neglected tropical diseases (NTDs) is leading to a revision of the related research agenda towards current and future control interventions and associated targets. In the journal Lancet Infectious Diseases, published 7 June 2016, LSTM's Professors Louis Niessen and Russell Stothard argue for a broad research and implementation approach in an efficient and equitable upscaling of the control of schistosomiasis and soil-transmitted helminthiasis in Sub-Saharan Africa.

Set within a global strategy of preventive chemotherapy as endorsed by WHO, routine co-administration of the anthelminthics praziquantel (PZQ) and albendazole (ALB), by mass drug administration, is the frontline public health tool against schistosomiasis and soil-transmitted helminthiasis (STH), respectively. In 2012 several significant pledges and commitments made at the London Declaration on NTDs with an additional World Health Assembly (WHA) resolution 65.21 that called for intensification of efforts to better rally resources and to ensure an adequate provision of medications.

In their Comments Professors Niessen and Stothard give thoughtful support to a Stanford-based economics study on the situation in Sub-Saharan Africa by Nathan Lo and colleagues, published in the same journal, that demonstrates most strikingly that, if 20% of the entire population would shift to integrated treatment, fully dovetailing PZQ and ALB treatments, programme synergies would lead to a 40% reduction in implementation costs. Also, the study shows that annual preventive chemotherapy against schistosomiasis to be very likely cost-effective in treatment of school-aged children already at a prevalence of 5% (current guidelines state 50%) and of entire communities at 15% prevalence. Annual mass drug administration against STH is very likely cost-effective in treatment of school-aged children at a prevalence of 20% and for the entire community only as high as 60% prevalence, given uncertainties (95% UI: 35·3-85·1%). The authors estimate that treatment needs for Africa are six-fold higher than current guidelines for PZQ and two- fold higher for ALB.

Nathan Lo, the leading scientist, from Stanford University School of Medicine, said: "This editorial provides a clear vision on how our study findings can be translated into the next stage of helminthiasis control and elimination. Their words are optimistic for what we can accomplish to address the disease burden of helminths, but also realistic with many suggestions on how to address the host of challenges in revision of treatment guidelines and scaling up of treatment programmes."

Niessen and Stothard argue that the consequences for country programming are immense. The involved total budgets and other investments needed will be substantial, a major undertaking, given the limited resources in other priority areas within the NTD programmes and other health issues. In all scenarios, increased drug subsidies, and donations from pharmaceutical companies, strong political will, increased logistical support and improved epidemiological surveillance to monitor for drug resistance are needed. Although treatment expansion is now shown both financially and geographically appealing, Professor Niessen and colleague point out that extension of coverage is also justified ethically. At lower prevalence levels the at-risk vulnerable populations may be living in poverty and be harder to reach and lower compliance will lead to less returns. Extra effort and resources needed in the national process to improve the quality of the existing expanded MDA programmes in all places. Professor Stothard emphasizes that strategies need to be in place to ensure that treatment fatigue within the community does not dampen the recipients' compliance and that their demand for treatment continues to complement the donor landscape and health system.

Professor Niessen said: "In revising preventive chemotherapy guidelines based on these new estimates, broader quantitative and qualitative evidence should also be collected and incorporated and collected - such as through the LSTM-coordinated COUNTDOWN programme -- to optimise the implementation of control campaigns, which may suffer low uptake. At least, these developments are new and essential steps in the promotion of universal access in prevention and treatment of neglected tropical diseases as also envisaged in the sustainable development goals."

You can read the article here.

Liverpool School of Tropical Medicine

Related Schistosomiasis Articles:

Using genomics to fight deadly parasitic disease
An international team of researchers, led by University of New Mexico Associate Professor Coenraad Adema, is now one step closer to eliminating a deadly parasitic disease responsible for killing hundreds of thousands of people around the world every year.
New protein could be key in fighting debilitating parasitic disease
A naturally occurring protein has been discovered that shows promise as a biocontrol weapon against schistosomiasis, one of the world's most prevalent parasitic diseases, Oregon State University researchers reported today in a new study.
Land use affects spread of schistosomiasis-carrying snails in Asia
To help inspire new ways of stopping the spread of schistosomiasis, researchers reporting in PLOS Neglected Tropical Diseases have studied the dispersal patterns of the snails that carry the infection.
Mystery of tropical human parasite swimming solved by Stanford researchers
Bioengineers combined live observation, mathematical insights and robots to reveal the movement of parasitic larvae that cause schistosomiasis, a neglected tropical disease affecting millions of people worldwide.
Modified HIV-1 virus can integrate into genome of parasitic flatworm
A modified form of the HIV-1 virus can integrate into the genome of the parasitic flatworm that causes the disease schistosomiasis, according to a new study published in PLOS Pathogens.
Novel schistosomiasis vaccine: New phase of clinical studies
The Oswaldo Cruz Foundation (Fiocruz) at Rio de Janeiro, Brazil, will start the phase II clinical trials of a vaccine for schistosomiasis, called 'Sm14 Vaccine.' The initiative is one of the health research and development projects prioritized by the World Health Organization (WHO), aiming to ensure the access of populations from developing countries to public health tools based on cutting edge technologies.
Stop the snails
A study published in PLOS NTDs reports that successful Schistosomiasis control programs over the past century relied, at least in part, on reducing the freshwater snails that are an essential host in the parasite life cycle.
Predatory prawns eliminate a major parasite more effectively than drugs alone
A new study upends the status quo to combatting schistosomiasis, which affects 250 million people worldwide.
Countdown economist and parasitologist call for efficient and equitable control of NTDs
The continuing permanence of major neglected tropical diseases (NTDs) is leading to a revision of the related research agenda towards current and future control interventions and associated targets.
Scientists receive $3.5 million to study drug resistance in a global parasitic disease
Dr. Tim Anderson at Texas Biomedical Research Institute and Dr.

Related Schistosomiasis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".